Episode #6: This Startup Is Changing the Way We Detect Cervical Cancer

Episode #6: This Startup Is Changing the Way We Detect Cervical Cancer

Author: by FemmeHealth Alliance April 24, 2025 Duration: 33:33

A few weeks ago, Ronald Vos and Nutte van Belzen, the founders of CC Diagnostics were at a major European medical congress when they were approached by a woman who didn’t work in science or medicine. She had bought an expensive delegate ticket, not to participate in the conference, but to seek help.

She had advanced cervical cancer. And she came in the hope that someone…anyone, at this gathering of gynaecologists and scientists might listen to her story and offer a lifeline.

We hope all those cases can be prevented,” co-founder Nutte van Belzen reflects.

That moment captures exactly why this episode matters.

Only 15% of women participate in cervical screenings, despite the fact that cervical cancer is entirely preventable through early detection and vaccination. The problem? Existing methods are invasive, uncomfortable, and all too easy to avoid until it’s too late.

In this conversation, the founders of CC Diagnostics share their journey: the personal experience and passion that fuels their mission, the technology they are building to make self-sampling accessible, and their vision for a world where diagnostics are not a privilege, but a right.

We also dive into:

* The overlooked challenges of building a diagnostics company.

* Why many investors hesitate and why that needs to change.

* Their roadmap for global access, including a pricing model for low- and middle-income countries (LMICs).

This isn’t just a conversation about tech or start-ups.

It’s about the human stories that push innovation forward, and the urgent need to act before another woman buys a ticket to beg for care.

🎧 Watch the full episode for a powerful and personal look at how we can, and must, do better in women’s health.

CC Diagnostics

CC Diagnostics (Netherlands) offers a clinically validated screening test, significantly improving cervical cancer detection rates to 97% (vs current market benchmark of 76%). Our product offers a 6x reduction in time per test for the diagnostic labs, dramatically reducing costs and improving efficiency. Our Methica test technology enables screening from home (with self-sampled material), unlocking a broader €5.5Bn screening market worldwide. We achieved commercial progress, with the first 2 international orders from leading CLIA labs in the US and UK.

CC Diagnostics (Netherlands)



Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

There's a vast, often overlooked frontier in business and innovation, and Blindspot Capital is mapping its terrain. This podcast digs into the ideas, trends, and tangible investment potential shaping the future of women's health, a sector that has historically been underfunded and underserved. Each episode moves beyond surface-level discussions to examine the systemic gaps and the consequential opportunities they create. You'll hear from founders, investors, researchers, and thinkers who are actively building and funding solutions in this space, sharing their on-the-ground experiences and hard-won insights. The conversations are grounded in the reality of entrepreneurship and market dynamics, exploring not just the "why" but the "how"-how new technologies are being applied, how businesses are scaling, and how capital can be deployed to generate both impact and returns. Tune in for a clear-eyed look at an area ripe for transformation, where understanding the blind spot isn't just about awareness, but about seeing a path forward for savvy builders and backers alike. This isn't a niche side conversation; it's a central dialogue about the next wave of growth in healthcare and technology, delivered through a podcast dedicated to substantive, forward-thinking analysis.
Author: Language: English Episodes: 18

Blindspot Capital
Podcast Episodes
What Real Science in Women’s Health Looks Like [not-audio_url] [/not-audio_url]

Duration: 25:15
Half the population experiences these conditions. Many are universal, recurring, and clinically significant. Yet in the eyes of too many investors, women’s health therapeutics remain “optional.”In this episode of Blindsp…
Blind Spot Capital is Here! [not-audio_url] [/not-audio_url]

Duration: 1:14
Blind Spot Capital Podcast TrailerWelcome to Blind Spot Capital, the podcast where health innovation meets investment insight. Every year, investors bet billions on the future of health but most still miss one of the big…
Episode #5: Transforming PostPartum Care with AI [not-audio_url] [/not-audio_url]

Duration: 52:08
In this conversation, Maryann and Astrid Gyllenkrok, CEO and Co-Founder of LEIA Health discuss the challenges of parenthood, particularly focusing on the postpartum experience and the need for better support systems for…
Episode #4: Breaking Barriers in Drug Delivery for Women [not-audio_url] [/not-audio_url]

Duration: 31:14
In this episode of FemmeHealth Founders, Maryann speaks with Dr. Lara Zibners, co-founder of Calla Lily Clinical Care, about the inadequacies in current drug delivery methods for women's health. Lara shares her personal…
Episode #3 - The Story Behind OvulaRing [not-audio_url] [/not-audio_url]

Duration: 40:25
In this episode of Notes to Selfe, we dive into the fascinating world of women's health innovation with Sebastian Alexander, founder and CEO of VivoSensMedical. We explore the journey of OvulaRing, a groundbreaking techn…
Femme Health Founders Episode #1 [not-audio_url] [/not-audio_url]

Duration: 29:43
Hormones rule our lives—from puberty to menopause, they influence everything from our mood to our health. But why do some women experience severe side effects while others don’t?In this episode of the FemmeHealth Founder…